Related Experiment Video
Updated: May 7, 2026

Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
Cost-effectiveness of catheter ablation for rhythm control of atrial fibrillation
Gord Blackhouse1, Nazila Assasi, Feng Xie
1PATH Research Institute, McMaster University, Suite 2000, 25 Main Street West, Hamilton, ON, Canada L8P 1H1 ; Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada L8S 4L8.
Insights
Catheter ablation for atrial fibrillation (AF) is cost-effective compared to antiarrhythmic drugs (AADs). It offers more quality-adjusted life years (QALYs) at an incremental cost of $59,194 per QALY.
Area of Science:
- Cardiology
- Health Economics
Background:
- Atrial fibrillation (AF) management often involves antiarrhythmic drugs (AADs).
- Patients may not respond adequately to AADs, necessitating alternative treatments.
- Catheter ablation is an alternative rhythm control strategy for AF.
Purpose of the Study:
- To assess the cost-effectiveness of catheter ablation versus AAD therapy for AF.
- To compare treatment strategies in patients with prior AAD failure.
- To inform clinical and economic decision-making for AF management.
Main Methods:
- An economic model comparing catheter ablation and AAD (amiodarone) was developed.
- A meta-analysis informed patient outcomes regarding normal sinus rhythm or AF.
- A 5-year Markov model simulated risks of ischemic stroke.
Main Results:
- Catheter ablation resulted in higher costs ($8,539) but fewer strokes and more QALYs (0.144) over 5 years.
- The incremental cost per QALY for ablation was $59,194.
- Ablation demonstrated high probability (89-90%) of cost-effectiveness at willingness-to-pay thresholds of $50,000-$100,000.
Conclusions:
- Pulmonary vein ablation for AF is a cost-effective strategy.
- Cost-effectiveness is achieved when willingness to pay for a QALY reaches $59,194.
- Catheter ablation offers a favorable economic profile for selected AF patients.
Abstract:
Objective. The objective of this study is to evaluate the cost-effectiveness of catheter ablation for rhythm control compared to antiarrhythmic drug (AAD) therapy in patients with atrial fibrillation (AF) who have previously failed on an AAD. Methods. An economic model was developed to compare (1) catheter ablation and (2) AAD (amiodarone 200 mg/day). At the end of the initial 12 month phase of the model, patients are classified as being in normal sinus rhythm or with AF, based on data from a meta-analysis. In the 5-year Markov phase of the model, patients are at risk of ischemic stroke each 3-month model cycle. Results. The model estimated that, compared to the AAD strategy, ablation had $8,539 higher costs, 0.033 fewer strokes, and 0.144 more QALYS over the 5-year time horizon. The incremental cost per QALY of ablation compared to AAD was estimated to be $59,194. The probability of ablation being cost-effective for willingness to pay thresholds of $50,000 and $100,000 was estimated to be 0.89 and 0.90, respectively. Conclusion. Based on current evidence, pulmonary vein ablation for treatment of AF is cost-effective if decision makers willingness to pay for a QALY is $59,194 or higher.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias V: Evaluating Dysrhythmias
Cardiac Catheterization I: Pre-Procedure Overview
Cardiopulmonary Resuscitation III: AED Use

